Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

TGF-α and IL-6 plasma levels selectively identify CML patients who fail to achieve an early molecular response or progress in the first year of therapy

Autor: Dale B. Watkins, Devendra K Hiwase, Chung H. Kok, Deborah L. White, D.T. T. Yeung, Gino Vairo, Randall H. Grose, Wendy N. Erber, Mark Biondo, Timothy P. Hughes, Kathy Fuller, Angel F. Lopez, John V. Reynolds, Samantha J. Busfield, Eva Nievergall, Teresa Sadras

Publikováno v: Leukemia. 30:1263-1272

Early molecular response (EMR, BCR-ABL1 (IS)≤10% at 3 months) is a strong predictor of outcome in imatinib-treated chronic phase chronic myeloid leukemia (CP-CML) patients, but for patients who transform early, 3 months may be too late for effectiv

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5e4e428a8d28fcaf88d018b221f4af85
https://doi.org/10.1038/leu.2016.34

Asciminib monotherapy as frontline treatment of chronic-phase chronic myeloid leukemia: results from the ASCEND study.

Autor: Yeung DT; Haematology Department, Royal Adelaide Hospital, Adelaide Medical School, University of Adelaide and Precision Cancer Medicine Theme, South Australian Health and Medical Research Institute, Adelaide, Australia., Shanmuganathan N; Haematology Department, Royal Adelaide Hospital, Adelaide Medical School, University of Adelaide and Precision Cancer Medicine Theme, South Australian Health and Medical Research Institute, Adelaide, Australia., Reynolds J; The Alfred Hospital and Australian Centre for Blood Diseases, Monash University, Melbourne, Australia., Branford S; Department of Genetics and Molecular Pathology, SA Pathology and Centre for Cancer Biology, University of South Australia, and Adelaide Medical School, University of Adelaide, Adelaide, Australia., Walia M; Australasian Leukaemia and Lymphoma Group, Melbourne, Australia., Yong ASM; Haematology Department, Royal Perth Hospital and University of Western Australia, Perth, Australia., Shortt J; Monash Haematology, Monash Health and Department of Medicine, School of Clinical Sciences at Monash Health, Monash University, Melbourne, Australia., Chee L; Department of Clinical Haematology, The Royal Melbourne Hospital and Peter MacCallum Cancer Centre and Department of Medicine, University of Melbourne, Melbourne, Australia., Viiala N; Haematology Department, Liverpool Hospital and University of New South Wales, Sydney, Australia., Cunningham I; Haematology Department, Concord Hospital and University of Sydney, Sydney, Australia., Ross DM; Haematology Department, Royal Adelaide Hospital, Adelaide Medical School, University of Adelaide and Precision Cancer Medicine Theme, South Australian Health and Medical Research Institute, Adelaide, Australia.; Haematology Department, Flinders Medical Centre and Flinders University, Adelaide, Australia., D'Souza A; Haematology Department, Wellington Hospital and University of Otago, Wellington, New Zealand., Wright M; Haematology Department, Fiona Stanley Hospital and University of Western Australia, Perth, Australia., Harrup R; Haematology Department, Royal Hobart Hospital and University of Tasmania, Hobart, Australia., Forsyth C; Haematology Department, Gosford Hospital, Gosford, Australia., Filshie R; Haematology Department, St Vincent's Hospital and University of Melbourne, Melbourne, Australia., Lane S; Cancer Care Services, Royal Brisbane and Women's Hospital and University of Queensland, Brisbane, Australia., Browett P; Haematology Department, Auckland Hospital and University of Auckland, Auckland, New Zealand., Grove C; Haematology Department, Sir Charles Gardiner Hospital and PathWest, University of Western Australia, Perth, Australia., Grigg AP; Haematology Department, Austin Hospital and University of Melbourne, Melbourne, Australia., Hughes TP; Haematology Department, Royal Adelaide Hospital, Adelaide Medical School, University of Adelaide and Precision Cancer Medicine Theme, South Australian Health and Medical Research Institute, Adelaide, Australia.

Publikováno v: Blood [Blood] 2024 Nov 07; Vol. 144 (19), pp. 1993-2001.

Myeloid neoplasms arising after methotrexate therapy for autoimmune rheumatological diseases do not exhibit poor-risk molecular features.

Autor: Wechalekar MD; Rheumatology Unit, Flinders Medical Centre, Adelaide, Australia.; Rheumatology Unit, Royal Adelaide Hospital, Adelaide, Australia.; College of Medicine and Public Health, Flinders University, Adelaide, Australia., Zhao LP; Department of Hematology, Hôpital Saint-Louis, Université de Paris, Assistance Publique des Hôpitaux de Paris (AP-HP), Paris, France.; Université de Paris, Institut de Recherche Saint-Louis, EMiLy, INSERM U1160, Paris, France.; CNRS, GDR3697 'Microenvironment of tumor niches-Micronit', Paris, France., Kutyna MM; Haematology Department, Central Adelaide Local Health Network, Adelaide, Australia.; Blood Cancer, Precision Medicine Theme, South Australian Health and Medical Research Institute, Adelaide, Australia.; Adelaide Medical School, University of Adelaide, Adelaide, Australia., Hong LE; Rheumatology Unit, Royal Adelaide Hospital, Adelaide, Australia.; Adelaide Medical School, University of Adelaide, Adelaide, Australia., Li J; Department of Medicine, Royal Adelaide Hospital, Adelaide, Australia., Hung K; Haematology Department, Central Adelaide Local Health Network, Adelaide, Australia.; Blood Cancer, Precision Medicine Theme, South Australian Health and Medical Research Institute, Adelaide, Australia.; Adelaide Medical School, University of Adelaide, Adelaide, Australia., Scott HS; Adelaide Medical School, University of Adelaide, Adelaide, Australia.; Centre for Cancer Biology, SA Pathology and University of South Australia, Adelaide, Australia.; Genetics and Molecular Pathology, SA Pathology, Adelaide, Australia., Brown A; Adelaide Medical School, University of Adelaide, Adelaide, Australia.; Centre for Cancer Biology, SA Pathology and University of South Australia, Adelaide, Australia.; Genetics and Molecular Pathology, SA Pathology, Adelaide, Australia., Hahn CC; Adelaide Medical School, University of Adelaide, Adelaide, Australia.; Centre for Cancer Biology, SA Pathology and University of South Australia, Adelaide, Australia.; Genetics and Molecular Pathology, SA Pathology, Adelaide, Australia., Kassahn K; Genetics and Molecular Pathology, SA Pathology, Adelaide, Australia., Ladon D; Genetics and Molecular Pathology, SA Pathology, Adelaide, Australia., Yeung DT; Haematology Department, Central Adelaide Local Health Network, Adelaide, Australia.; Blood Cancer, Precision Medicine Theme, South Australian Health and Medical Research Institute, Adelaide, Australia.; Adelaide Medical School, University of Adelaide, Adelaide, Australia., Thomas D; Haematology Department, Central Adelaide Local Health Network, Adelaide, Australia.; Blood Cancer, Precision Medicine Theme, South Australian Health and Medical Research Institute, Adelaide, Australia.; Adelaide Medical School, University of Adelaide, Adelaide, Australia., Patnaik M; Division of Hematology, Mayo Clinic, Rochester, MN, USA., Proudman S; Rheumatology Unit, Royal Adelaide Hospital, Adelaide, Australia.; Adelaide Medical School, University of Adelaide, Adelaide, Australia., Ades L; Department of Hematology, Hôpital Saint-Louis, Université de Paris, Assistance Publique des Hôpitaux de Paris (AP-HP), Paris, France.; Université de Paris, Institut de Recherche Saint-Louis, INSERM U944, Paris, France., Shah MV; Division of Hematology, Mayo Clinic, Rochester, MN, USA., Kok CH; Adelaide Medical School, University of Adelaide, Adelaide, Australia.; Centre for Cancer Biology, SA Pathology and University of South Australia, Adelaide, Australia.; Genetics and Molecular Pathology, SA Pathology, Adelaide, Australia., Hiwase DK; Haematology Department, Central Adelaide Local Health Network, Adelaide, Australia. Devendra.hiwase@sa.gov.au.; Blood Cancer, Precision Medicine Theme, South Australian Health and Medical Research Institute, Adelaide, Australia. Devendra.hiwase@sa.gov.au.; Adelaide Medical School, University of Adelaide, Adelaide, Australia. Devendra.hiwase@sa.gov.au.; Centre for Cancer Biology, SA Pathology and University of South Australia, Adelaide, Australia. Devendra.hiwase@sa.gov.au.

Publikováno v: Blood cancer journal [Blood Cancer J] 2024 Jul 19; Vol. 14 (1), pp. 116. Date of Electronic Publication: 2024 Jul 19.

IDH-mutant myeloid neoplasms are associated with seronegative rheumatoid arthritis and innate immune activation.

Autor: Hong LE; Rheumatology Unit, Royal Adelaide Hospital, Adelaide, Australia.; Adelaide Medical School, University of Adelaide, Adelaide, Australia., Wechalekar MD; Rheumatology Unit, Royal Adelaide Hospital, Adelaide, Australia.; Rheumatology Unit, Flinders Medical Centre, Adelaide, Australia.; College of Medicine and Public Health, Flinders University, Adelaide, Australia., Kutyna M; Haematology Department, Central Adelaide Local Health Network, Adelaide, Australia.; Blood Cancer, Precision Medicine Theme, South Australian Health and Medical Research Institute, Adelaide, Australia., Small A; College of Medicine and Public Health, Flinders University, Adelaide, Australia., Lim K; Adelaide Medical School, University of Adelaide, Adelaide, Australia.; Blood Cancer, Precision Medicine Theme, South Australian Health and Medical Research Institute, Adelaide, Australia., Thompson-Peach C; Adelaide Medical School, University of Adelaide, Adelaide, Australia.; Blood Cancer, Precision Medicine Theme, South Australian Health and Medical Research Institute, Adelaide, Australia., Li JJ; Haematology Department, Central Adelaide Local Health Network, Adelaide, Australia., Chhetri R; Adelaide Medical School, University of Adelaide, Adelaide, Australia.; Haematology Department, Central Adelaide Local Health Network, Adelaide, Australia., Scott HS; Adelaide Medical School, University of Adelaide, Adelaide, Australia.; Centre for Cancer Biology, SA Pathology and University of South Australia, Adelaide, Australia.; Genetics and Molecular Pathology, SA Pathology, Adelaide, Australia., Brown A; Adelaide Medical School, University of Adelaide, Adelaide, Australia.; Centre for Cancer Biology, SA Pathology and University of South Australia, Adelaide, Australia.; Genetics and Molecular Pathology, SA Pathology, Adelaide, Australia., Hahn CN; Adelaide Medical School, University of Adelaide, Adelaide, Australia.; Centre for Cancer Biology, SA Pathology and University of South Australia, Adelaide, Australia.; Genetics and Molecular Pathology, SA Pathology, Adelaide, Australia., Yeung DT; Adelaide Medical School, University of Adelaide, Adelaide, Australia.; Haematology Department, Central Adelaide Local Health Network, Adelaide, Australia.; Blood Cancer, Precision Medicine Theme, South Australian Health and Medical Research Institute, Adelaide, Australia., Sajid S; Department of Drug Design and Pharmacology, University of Copenhagen, Copenhagen, Denmark., Robinson N; Centre for Cancer Biology, SA Pathology and University of South Australia, Adelaide, Australia., Thomas R; Frazer Institute, University of Queensland, Brisbane, Australia., Branford S; Adelaide Medical School, University of Adelaide, Adelaide, Australia.; Centre for Cancer Biology, SA Pathology and University of South Australia, Adelaide, Australia.; Genetics and Molecular Pathology, SA Pathology, Adelaide, Australia., D'Andrea RJ; Centre for Cancer Biology, SA Pathology and University of South Australia, Adelaide, Australia., Samaraweera SE; Centre for Cancer Biology, SA Pathology and University of South Australia, Adelaide, Australia., Patnaik M; Division of Hematology, Mayo Clinic, Rochester, MN., Proudman S; Rheumatology Unit, Royal Adelaide Hospital, Adelaide, Australia.; Adelaide Medical School, University of Adelaide, Adelaide, Australia., Thomas D; Adelaide Medical School, University of Adelaide, Adelaide, Australia.; Haematology Department, Central Adelaide Local Health Network, Adelaide, Australia.; Blood Cancer, Precision Medicine Theme, South Australian Health and Medical Research Institute, Adelaide, Australia., Kok CH; Adelaide Medical School, University of Adelaide, Adelaide, Australia.; Blood Cancer, Precision Medicine Theme, South Australian Health and Medical Research Institute, Adelaide, Australia.; Centre for Cancer Biology, SA Pathology and University of South Australia, Adelaide, Australia., Shah MV; Division of Hematology, Mayo Clinic, Rochester, MN., Hiwase DK; Adelaide Medical School, University of Adelaide, Adelaide, Australia.; Haematology Department, Central Adelaide Local Health Network, Adelaide, Australia.; Blood Cancer, Precision Medicine Theme, South Australian Health and Medical Research Institute, Adelaide, Australia.

Publikováno v: Blood [Blood] 2024 May 02; Vol. 143 (18), pp. 1873-1877.